Acute myeloid leukemia following therapy of Hodgkin's disease with radiotherapy and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)

被引：0
|
作者：
Lipton, JH
Gospodarowicz, M
Reingold, S
机构：
[1] PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT MED,TORONTO,ON M4X 1K9,CANADA
[2] PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT RADIAT ONCOL,TORONTO,ON M4X 1K9,CANADA
[3] UNIV TORONTO,TORONTO,ON,CANADA
[4] PEEL MEM HOSP,DEPT MED,BRAMPTON,ON,CANADA
来源：
HEMATOLOGICAL ONCOLOGY | 1996年 / 14卷 / 01期
关键词：
acute myeloid leukemia; Hodgkin's disease; ABVD; radiation therapy; secondary leukemia;
D O I：
10.1002/(SICI)1099-1069(199603)14:1<29::AID-HON561>3.0.CO;2-J
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A 26-year-old man developed myelodysplasia rapidly progressing to acute myelomonocytic leukemia 3 years after receiving three cycles of ABVD chemotherapy and upper mantle and upper abdomen radiotherapy for stage IA Hodgkin's disease. This represents the fourth such case reported. The risk of secondary AML after ABVD or radiation therapy is discussed.
引用
收藏
页码：29 / 31
页数：3
相关论文
共 50 条
  • [31] Short duration filgrastim (G-CSF) therapy (24 days) is adequate to maintain dose intensity in Hodgkin's lymphoma patients treated with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).
    Kammer, Lynne S.
    Bavisi, Seema
    Lawton, Jessica
    Uhlig, William
    Carro, George
    Grinblatt, David L.
    BLOOD, 2006, 108 (11) : 255B - 255B
  • [32] Phase I study of gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin's disease (HD):: Increased pulmonary toxicity compared with ABVD.
    Friedberg, JW
    Neuberg, D
    Bendell, C
    Miyata, S
    McCauley, M
    Fisher, DC
    Takvorian, T
    Canellos, GP
    BLOOD, 2002, 100 (11) : 159A - 159A
  • [33] Non-growing follicle density is increased following adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy in the adult human ovary
    McLaughlin, M.
    Kelsey, T. W.
    Wallace, W. H. B.
    Anderson, R. A.
    Telfer, E. E.
    HUMAN REPRODUCTION, 2017, 32 (01) : 165 - 174
  • [34] Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy
    Gandikota, Neetha
    Hartridge-Lambert, Sidonie
    Migliacci, Jocelyn C.
    Yahalom, Joachim
    Portlock, Carol S.
    Schoeder, Heiko
    CANCER, 2015, 121 (12) : 1985 - 1992
  • [35] Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma:: Final results of the GHSG HD7 trial
    Engert, Andreas
    Franklin, Jeremy
    Eich, Hans Theodor
    Brillant, Corinne
    Sehlen, Susanne
    Cartoni, Claudio
    Herrmann, Richard
    Pfreundschuh, Michael
    Sieber, Markus
    Tesch, Hans
    Franke, Astrid
    Koch, Peter
    de Wit, Maike
    Paulus, Ursula
    Hasenclever, Dirk
    Loeffler, Markus
    Mueller, Rolf-Peter
    Mueller-Hermelink, Hans Konrad
    Duehmke, Eckhart
    Diehl, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) : 3495 - 3502
  • [36] Treatment of childhood Hodgkin's disease with ABVD without radiotherapy
    Behrendt, H
    Brinkhuis, M
    VanLeeuwen, EF
    MEDICAL AND PEDIATRIC ONCOLOGY, 1996, 26 (04): : 244 - 248
  • [37] ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) as front-line therapy for Hodgkins lymphoma in Hispanic patients: A single center experience from Texas-Mexico Border.
    Gaur, Sumit
    Philipovskiy, Alexander
    Dwivedi, Alok Kumar
    Eiring, Ana
    Onyedika, Umeanaeto
    Orazi, Attilio
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Alone in Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma: Do We Really Have Robust Data?
    Basaran, Gul
    Agaoglu, Fulya
    Basaran, Mert
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) : E485 - E486
  • [39] Modified Endothelial Activation and Stress Index: A New Predictor for Survival Outcomes in Classical Hodgkin Lymphoma Treated with Doxorubicin-Bleomycin-Vinblastine-Dacarbazine-Based Therapy
    Hunutlu, Fazil cagri
    Oztop, Hikmet
    Gursoy, Vildan
    Ersal, Tuba
    Elgun, Ezel
    Yavuz, Seyma
    Ekizoglu, Selin Ildemir
    Ekizoglu, Azim Ali
    Ozkocaman, Vildan
    Ozkalemkas, Fahir
    DIAGNOSTICS, 2025, 15 (02)
  • [40] Balancing Risks and Benefits of Therapy for Patients with Favorable-Risk Limited-Stage Hodgkin Lymphoma: The Role of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Chemotherapy Alone
    Hay, Annette E.
    Meyer, Ralph M.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (01) : 49 - +
12345